| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T2 |
0-105 |
Sentence |
denotes |
Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. |
| T2 |
0-105 |
Sentence |
denotes |
Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. |
| T2 |
0-283 |
Sentence |
denotes |
Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. |
| TextSentencer_T3 |
106-283 |
Sentence |
denotes |
Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. |
| T3 |
106-283 |
Sentence |
denotes |
Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. |
